Michaël Vlemmix

Michaël is a Bio-Engineer (Cell & Gene Biotechnology) holding a Master in Management from the Antwerp Management School. He started his professional career in 2012 at Oxypoint, a medical device spin-off of the University of Antwerp. In February 2016, he switched to investment banking at KBC Securities as a Biotech/Healthcare analyst where he worked on initial public offerings and several other capital market transactions while providing coverage of the Benelux Biotech & Healthcare stocks.

Late 2017, Michaël joined Gimv and is active in the Life Sciences platform. Today he is representing Gimv on the board of directors of Precirix (BE), Complement Therapeutics (DE/UK) and Paleo (BE) while supporting several other portfolio companies.